Oncotelic Therapeutics: presents PDAOAI platform and HCC research

What happened

• Oncotelic Therapeutics reported that on Oct 7, 2026 and Oct 8, 2026 representatives presented information at Drug Discovery 2026 in Burlingame, California.
• The company presented material on its PDAOAI platform and on hepatocellular carcinoma ("HCC") research, including a four-gene mTOR-related signature.

Key details

• Scott Myers, Product Manager, described the PDAOAI search and evidence-aggregation workflow and an index of approximately 29 million PubMed abstracts using Partitioned Literature Aggregation.
• Saran Saund, Chief Business Officer, presented a 4-gene mTOR-related signature comprising FKBP1A, EIF4E, RRAGC, and PPARGC1A; the signature was associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort.
• Presentations noted that the retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies.
• The presentations described "BIO REBOOT," an initiative inviting researchers to propose therapeutic research projects using PDAOAI; selected projects may qualify for startup funding and development support, subject to scientific review, available resources, and agreed terms.

Why it may matter

• Item 8.01 (Other events) was reported; the item covers the furnished presentations and related materials about the PDAOAI platform, HCC research, and the BIO REBOOT initiative.
• The filing does not show why the insider traded or why the company acted.